查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1612838

感染疾病的體外診斷的全球市場:產業分析，規模，佔有率，成長，趨勢，預測(2024年～2031年)

Infectious Disease In-vitro Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 188 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

預計2024年全球傳染病體外診斷市場規模將達445億美元，2024年至2031年預測期間複合年增長率為4.7%，2031年將達612億美元。

傳染病體外診斷市場是指用於檢測細菌、病毒、真菌、寄生蟲等病原體引起的傳染病的診斷測試。這些診斷測試對於傳染病的早期發現、管理和治療至關重要。該市場的推動因素包括全球傳染病患者病率上升、診斷技術的技術進步以及對快速準確診斷工具的需求不斷增長，特別是在全球大流行之後。該市場包括分子診斷、免疫分析和微生物檢測等各領域。

有幾個因素促進了全球傳染病體外診斷市場的發展，包括傳染病發病率的上升（尤其是在發展中地區）以及醫療基礎設施的成長。人們對早期診斷的認識不斷提高，以及對傳染病即時檢測（POC​​T）的需求不斷增長，進一步推動了市場的成長。 COVID-19、結核病、愛滋病毒和瘧疾等疾病的發生率不斷增加，也增加了對準確、快速診斷工具的需求。此外，分子診斷和下一代定序（NGS）的技術進步預計將推動市場向前發展。

傳染病體外診斷市場提供了巨大的商機，特別是在新興國家，傳染病負擔的日益增加正在推動對更好診斷工具的需求。分子診斷的進步，包括基於 PCR 的技術和 CRISPR，為創新和擴展提供了新的機會。此外，個人化醫療的不斷增長趨勢和多重測試平台的發展為市場進入者提供了成長途徑。此外，診斷公司和醫療保健提供者之間日益加強的合作預計將為市場擴張帶來新的機會。

本報告提供全球感染疾病的體外診斷市場相關調查，提供各產品類型，各技術，各用途，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 摘要整理

第2章 市場概要

  • 市場範圍和定義
  • 市場動態
  • 宏觀經濟要素
  • COVID-19影響分析
  • 預測要素- 相關性及影響

第3章 附加價值的洞察

第4章 全球感染疾病的體外診斷市場預測:實際成果(2019年～2023年)及預測(2024年～2031年)

  • 主要的焦點
  • 市場規模(10億美元)分析與預測
  • 全球感染疾病的體外診斷市場預測:各產品類型
  • 市場魅力分析:各產品類型
  • 全球感染疾病的體外診斷市場預測:各技術
  • 市場魅力分析:各技術
  • 全球感染疾病的體外診斷市場預測:各用途
  • 市場魅力分析:各用途
  • 全球感染疾病的體外診斷市場預測:各終端用戶
  • 市場魅力分析:各終端用戶

第5章 全球感染疾病的體外診斷市場預測:各地區

  • 主要的焦點
  • 過去的市場規模(10億美元)分析，各地區，2019年～2023年
  • 目前市場規模(10億美元)的分析與預測，各地區，2024年～2031年
  • 市場魅力分析:各地區

第6章 北美的感染疾病的體外診斷市場預測:實際成果(2019年～2023年)及預測(2024年～2031年)

第7章 歐洲的感染疾病的體外診斷市場預測:實際成果(2019年～2023年)及預測(2024年～2031年)

第8章 東亞的感染疾病的體外診斷市場預測:實際成果(2019年～2023年)及預測(2024年～2031年)

第9章 南亞及大洋洲的感染疾病的體外診斷市場預測:實際成果(2019年～2023年)及預測(2024年～2031年)

第10章 南美的感染疾病的體外診斷市場預測:實際成果(2019年～2023年)及預測(2024年～2031年)

第11章 中東·非洲的感染疾病的體外診斷市場預測:實際成果(2019年～2023年)及預測(2024年～2031年)

第12章 競爭情形

  • 市場佔有率分析，2023年
  • 市場結構
  • 企業簡介(詳細內容- 概要，財務，策略，最近的趨勢)
    • QIAGEN
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche, Ltd.
    • Hologic, Inc. (Gen Probe)
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • OraSure Technologies, Inc.

第13章 附錄

簡介目錄
Product Code: PMRREP33205

Persistence Market Research has recently released a comprehensive report on the global Infectious Disease In-vitro Diagnostics (IVD) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Infectious Disease In-vitro Diagnostics Market Size (2024E): US$ 44.5 Bn
  • Projected Market Value (2031F): US$ 61.2 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.7%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

The Infectious Disease In-vitro Diagnostics market refers to diagnostic tests used for detecting infections caused by pathogens such as bacteria, viruses, fungi, and parasites. These diagnostic tests are essential in the early detection, management, and treatment of infectious diseases. The market is driven by rising global infectious disease prevalence, technological advancements in diagnostic technologies, and an increasing need for rapid and accurate diagnostic tools, especially in the wake of global pandemics. The market encompasses various segments, including molecular diagnostics, immunoassays, and microbiology testing.

Market Growth Drivers:

Several factors are contributing to the growth of the global Infectious Disease IVD market, including the rising incidence of infectious diseases, especially in developing regions, and growing healthcare infrastructure. Increasing awareness about early diagnosis and the growing demand for point-of-care testing (POCT) for infectious diseases are further propelling market growth. The need for accurate and rapid diagnostic tools is also rising due to the increasing frequency of outbreaks of diseases such as COVID-19, tuberculosis, HIV, and malaria. Additionally, technological advancements in molecular diagnostics and next-generation sequencing (NGS) are expected to drive the market forward.

Market Restraints:

Despite its growth potential, the Infectious Disease IVD market faces challenges such as high costs associated with advanced diagnostic tests, particularly in low-income regions. Regulatory hurdles in some countries, along with the need for extensive validation and certification of diagnostic products, may also limit market expansion. Moreover, the lack of awareness in remote areas regarding the availability and benefits of in-vitro diagnostics poses a barrier to the widespread adoption of diagnostic tools.

Market Opportunities:

The Infectious Disease IVD market presents significant opportunities, particularly in emerging economies, where the demand for better diagnostic tools is growing due to the rising burden of infectious diseases. Advancements in molecular diagnostics, including PCR-based technologies and CRISPR, offer new opportunities for innovation and expansion. Further, the increasing trend toward personalized medicine and the development of multiplex testing platforms provide growth avenues for market players. Additionally, the rise in collaborations between diagnostic companies and healthcare providers is expected to open new opportunities for market expansion.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global Infectious Disease IVD market?
  • Which diagnostic technologies and testing platforms are leading the market in terms of demand and revenue?
  • How are advancements in molecular diagnostics and PCR technologies influencing the Infectious Disease IVD market?
  • Who are the leading players in the Infectious Disease IVD market, and what strategies are they employing to maintain their market positions?
  • What are the emerging trends and future prospects in the global Infectious Disease IVD market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Infectious Disease IVD market, such as Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers, are focusing on enhancing their product portfolios, including rapid diagnostics and molecular testing platforms. These companies are investing in innovative technologies such as real-time PCR, next-generation sequencing (NGS), and point-of-care testing solutions. Collaborations with healthcare providers, research institutions, and public health organizations are critical to expanding market reach. Moreover, focusing on regulatory compliance, product differentiation, and technological advancements will help companies maintain a competitive edge and capitalize on the growing demand for efficient and accurate infectious disease diagnostics.

Key Companies Profiled:

  • QIAGEN
  • Becton, Dickinson and Company
  • bioMerieux SA
  • F. Hoffmann-La Roche, Ltd.
  • Hologic, Inc. (Gen Probe)
  • Abbott
  • Quidel Corporation
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • OraSure Technologies, Inc.

Infectious Disease In-vitro Diagnostics Industry Segmentation

By Product Type

  • Instruments
  • Reagents
  • Software and Services

By Technology

  • Immunoassay
  • Molecular Diagnostics
  • Microbiology

By Application

  • MRSA
  • Clostridium Difficile
  • Respiratory Virus
  • TB and Drug-resistant TB
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19

By End User

  • Point-of-care
  • Central Laboratories

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Infectious Disease In-Vitro Diagnostics Market Snapshot, 2024 - 2031
  • 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. Parent Market Analysis
  • 3.6. PESTLE Analysis
  • 3.7. Porter's Five Force Analysis

4. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024 - 2031
  • 4.3. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019 - 2023
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
      • 4.3.3.1. Instruments
      • 4.3.3.2. Reagents
      • 4.3.3.3. Software and Services
  • 4.4. Market Attractiveness Analysis: Product Type
  • 4.5. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Technology
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019 - 2023
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
      • 4.5.3.1. Immunoassay
      • 4.5.3.2. Molecular Diagnostics
      • 4.5.3.3. Microbiology
      • 4.5.3.4. Others
  • 4.6. Market Attractiveness Analysis: Technology
  • 4.7. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Application
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2023
    • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
      • 4.7.3.1. MRSA
      • 4.7.3.2. Clostridium Difficile
      • 4.7.3.3. Respiratory Virus
      • 4.7.3.4. TB and Drug-resistant TB
      • 4.7.3.5. Gonorrhea
      • 4.7.3.6. HPV
      • 4.7.3.7. HIV
      • 4.7.3.8. Hepatitis C
      • 4.7.3.9. Hepatitis B
      • 4.7.3.10. COVID-19
      • 4.7.3.11. Others
  • 4.8. Market Attractiveness Analysis: Application
  • 4.9. Global Infectious Disease In-Vitro Diagnostics Market Outlook: End User
    • 4.9.1. Introduction / Key Findings
    • 4.9.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2023
    • 4.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
      • 4.9.3.1. Point-of-care
      • 4.9.3.2. Central Laboratories
      • 4.9.3.3. Others
  • 4.10. Market Attractiveness Analysis: End User

5. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2023
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024 - 2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 6.2.1. By Country
    • 6.2.2. By Product Type
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 6.4.1. Instruments
    • 6.4.2. Reagents
    • 6.4.3. Software and Services
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 6.5.1. Immunoassay
    • 6.5.2. Molecular Diagnostics
    • 6.5.3. Microbiology
    • 6.5.4. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 6.6.1. MRSA
    • 6.6.2. Clostridium Difficile
    • 6.6.3. Respiratory Virus
    • 6.6.4. TB and Drug-resistant TB
    • 6.6.5. Gonorrhea
    • 6.6.6. HPV
    • 6.6.7. HIV
    • 6.6.8. Hepatitis C
    • 6.6.9. Hepatitis B
    • 6.6.10. COVID-19
    • 6.6.11. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 6.7.1. Point-of-care
    • 6.7.2. Central Laboratories
    • 6.7.3. Others
  • 6.8. Market Attractiveness Analysis

7. Europe Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 7.2.1. By Country
    • 7.2.2. By Product Type
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 7.4.1. Instruments
    • 7.4.2. Reagents
    • 7.4.3. Software and Services
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 7.5.1. Immunoassay
    • 7.5.2. Molecular Diagnostics
    • 7.5.3. Microbiology
    • 7.5.4. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 7.6.1. MRSA
    • 7.6.2. Clostridium Difficile
    • 7.6.3. Respiratory Virus
    • 7.6.4. TB and Drug-resistant TB
    • 7.6.5. Gonorrhea
    • 7.6.6. HPV
    • 7.6.7. HIV
    • 7.6.8. Hepatitis C
    • 7.6.9. Hepatitis B
    • 7.6.10. COVID-19
    • 7.6.11. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 7.7.1. Point-of-care
    • 7.7.2. Central Laboratories
    • 7.7.3. Others
  • 7.8. Market Attractiveness Analysis

8. East Asia Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 8.2.1. By Country
    • 8.2.2. By Product Type
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 8.4.1. Instruments
    • 8.4.2. Reagents
    • 8.4.3. Software and Services
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 8.5.1. Immunoassay
    • 8.5.2. Molecular Diagnostics
    • 8.5.3. Microbiology
    • 8.5.4. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 8.6.1. MRSA
    • 8.6.2. Clostridium Difficile
    • 8.6.3. Respiratory Virus
    • 8.6.4. TB and Drug-resistant TB
    • 8.6.5. Gonorrhea
    • 8.6.6. HPV
    • 8.6.7. HIV
    • 8.6.8. Hepatitis C
    • 8.6.9. Hepatitis B
    • 8.6.10. COVID-19
    • 8.6.11. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 8.7.1. Point-of-care
    • 8.7.2. Central Laboratories
    • 8.7.3. Others
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 9.2.1. By Country
    • 9.2.2. By Product Type
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 9.4.1. Instruments
    • 9.4.2. Reagents
    • 9.4.3. Software and Services
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 9.5.1. Immunoassay
    • 9.5.2. Molecular Diagnostics
    • 9.5.3. Microbiology
    • 9.5.4. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 9.6.1. MRSA
    • 9.6.2. Clostridium Difficile
    • 9.6.3. Respiratory Virus
    • 9.6.4. TB and Drug-resistant TB
    • 9.6.5. Gonorrhea
    • 9.6.6. HPV
    • 9.6.7. HIV
    • 9.6.8. Hepatitis C
    • 9.6.9. Hepatitis B
    • 9.6.10. COVID-19
    • 9.6.11. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 9.7.1. Point-of-care
    • 9.7.2. Central Laboratories
    • 9.7.3. Others
  • 9.8. Market Attractiveness Analysis

10. Latin America Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 10.2.1. By Country
    • 10.2.2. By Product Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 10.4.1. Instruments
    • 10.4.2. Reagents
    • 10.4.3. Software and Services
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 10.5.1. Immunoassay
    • 10.5.2. Molecular Diagnostics
    • 10.5.3. Microbiology
    • 10.5.4. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 10.6.1. MRSA
    • 10.6.2. Clostridium Difficile
    • 10.6.3. Respiratory Virus
    • 10.6.4. TB and Drug-resistant TB
    • 10.6.5. Gonorrhea
    • 10.6.6. HPV
    • 10.6.7. HIV
    • 10.6.8. Hepatitis C
    • 10.6.9. Hepatitis B
    • 10.6.10. COVID-19
    • 10.6.11. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 10.7.1. Point-of-care
    • 10.7.2. Central Laboratories
    • 10.7.3. Others
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 11.2.1. By Country
    • 11.2.2. By Product Type
    • 11.2.3. By Technology
    • 11.2.4. By Application
    • 11.2.5. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 11.4.1. Instruments
    • 11.4.2. Reagents
    • 11.4.3. Software and Services
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 11.5.1. Immunoassay
    • 11.5.2. Molecular Diagnostics
    • 11.5.3. Microbiology
    • 11.5.4. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 11.6.1. MRSA
    • 11.6.2. Clostridium Difficile
    • 11.6.3. Respiratory Virus
    • 11.6.4. TB and Drug-resistant TB
    • 11.6.5. Gonorrhea
    • 11.6.6. HPV
    • 11.6.7. HIV
    • 11.6.8. Hepatitis C
    • 11.6.9. Hepatitis B
    • 11.6.10. COVID-19
    • 11.6.11. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 11.7.1. Point-of-care
    • 11.7.2. Central Laboratories
    • 11.7.3. Others
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Becton, Dickinson and Company
    • 12.3.3. bioMerieux SA
    • 12.3.4. F. Hoffmann-La Roche, Ltd.
    • 12.3.5. Hologic, Inc. (Gen Probe)
    • 12.3.6. Abbott
    • 12.3.7. Quidel Corporation
    • 12.3.8. Siemens Healthineers AG
    • 12.3.9. Bio-Rad Laboratories, Inc.
    • 12.3.10. Danaher
    • 12.3.11. OraSure Technologies, Inc.

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations